Heike Keilhack

6.9k citations
48 papers · 3.3k · 2 hit papers · h-index 25

Impact in

    • Epigenetics and DNA Methylation
    • Protein Tyrosine Phosphatases
    • Cancer-related gene regulation
    • Chromatin Remodeling and Cancer
    • RNA modifications and cancer
    • Histone Deacetylase Inhibitors Research
    • Protein Degradation and Inhibitors
  • Immunology top 5%
    • Galectins and Cancer Biology

Papers in

    • Cancer-related gene regulation 18
    • Epigenetics and DNA Methylation 15
    • Chromatin Remodeling and Cancer 12
    • Protein Tyrosine Phosphatases 10
    • RNA modifications and cancer 8
    • PARP inhibition in cancer therapy 8

Heike Keilhack

46 papers receiving 3.2k citations

Heike Keilhack's Hit Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study 2018 · 462 citations
4620+4+8Years since publication100200300400500

Peers

Heike Keilhack
Comparison fields: 5 of 99
  • Molecular Biology 2.7k
  • Immunology 566
  • Pathology and Forensic Medicine 373
  • Oncology 565
  • Cancer Research 227
Replace Suzanne Schubbert with:
Suzanne Schubbert United States
Adina Vultur United States
Mari Iida United States
Steven R. Whittaker United Kingdom
Dan Niculescu‐Duvaz United Kingdom
Caterina Nardella United States
Adam Kashishian United States
Ayana Sawai United States
Deric L. Wheeler United States
Keith Orford United States
Heike Keilhack relative to Suzanne Schubbert United States Suzanne Schubbert's profile →
Citations per field
00.5×
Suzanne Schubbert · 1×
Citations per year

Countries citing papers authored by Heike Keilhack

Since Specialization
Citations

This map shows the geographic impact of Heike Keilhack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Keilhack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Keilhack more than expected).

Fields of papers citing papers by Heike Keilhack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Keilhack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Keilhack. The network helps show where Heike Keilhack may publish in the future.

Co-authors

The 25 scholars most cited alongside Heike Keilhack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heike Keilhack Line = papers co-authored together Heike Keilhack links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Hit paper breakdown →
2013589
2
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Hit paper breakdown →
2018462
3 2005230
4 2005211
5 2016129
6 2017128
7 1998127
8 2001124
9 2012116
10 1999100
11 201597
12 201697
13 200989
14 201687
15 199782
16 200164
17 201659
18 201455
19 200055
20 201154

About Heike Keilhack

Heike Keilhack is a scholar working on Molecular Biology, Oncology, Immunology, Electrical and Electronic Engineering and Pathology and Forensic Medicine, having authored 48 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer-related gene regulation (18 papers), Epigenetics and DNA Methylation (15 papers), Chromatin Remodeling and Cancer (12 papers), Protein Tyrosine Phosphatases (10 papers), PARP inhibition in cancer therapy (8 papers), RNA modifications and cancer (8 papers), Galectins and Cancer Biology (6 papers) and Integrated Circuits and Semiconductor Failure Analysis (4 papers). The work is most often cited by research in Molecular Biology (2.7k citations), Immunology (566 citations), Pathology and Forensic Medicine (373 citations), Oncology (565 citations) and Cancer Research (227 citations). Heike Keilhack has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Robert A. Copeland, Sarah K. Knutson, Tim J. Wigle, Frank‐D. Böhmer, Kevin W. Kuntz, Mikel P. Moyer, Richard Chesworth, Benjamin G. Neel, Victoria M. Richon and Roy M. Pollock. Their work appears in journals such as Journal of Biological Chemistry, Molecular Cancer Therapeutics, PLoS ONE, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact